Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.
|Bias||Author's judgement||Support for judgement|
|Quote: "The biostatistician generated random numbers using block randomization with block sizes of 4 using SAS program and allocated eligible patients either to Test group or Control group" (report) "Method of Generating Random Sequence: Computer generated randomization. Method of concealment: Centralized" (registry)
Comment: Allocation sequence random. Allocation sequence concealed.
|Deviations from intervention||
|Quote: “open-label design”
Comment: Unblinded study (participants and personnel/carers).
Deviations from intended intervention arising because of the study context:
No participant cross-over.
No information on administration of co-interventions of interest: antivirals, biologics, and corticosteroids.
Hence, no information on whether deviations arose because of the trial context.
Data for all the outcomes were analyzed using intention-to-treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention.
Risk assessed to be some concerns for the outcomes: Mortality (D28). Incidence of viral negative conversion (D7). Adverse events. Serious adverse events.
|Missing outcome data||
|Comment: 100 participants randomized; 100 participants analyzed.
Data available for all or nearly all participants.
Risk assessed to be low for the outcomes: Mortality (D28). Incidence of viral negative conversion (D7). Adverse events. Serious adverse events.
|Measurement of the outcome||
|Comment: Method of measuring the outcome probably appropriate.
Measurement or ascertainment of outcome probably does not differ between groups.
Unblinded study (outcome assessor).
MORTALITY, VIRAL NEGATIVE CONVERSION
Mortality and viral negative conversion are observer-reported outcomes not involving judgement.
Risk assessed to be low for the outcomes: Mortality (D28). Incidence of viral negative conversion (D7).
SERIOUS ADVERSE EVENTS
Death was the only serious adverse event reported. This does not involve judgement.
Risk assessed to be low for the outcome: Serious adverse events
The authors reported on adverse events that may contain both clinically- and laboratory-detected events, which can be influenced by knowledge of the intervention assignment.
Risk assessed to be some concerns for the outcome: Adverse events.
|Selection of the reported results||
|Comment: The protocol and statistical analysis plan were not available. The registry was available but the prospective version was not accessible and it is unclear whether outcome measures were not changed between the original and final version of the registry.
No information on whether the result was selected from multiple outcome measurements or analyses of the data.
No information on whether the trial was analyzed as pre-specified.
Risk assessed to be some concerns for the outcome: Mortality (D28). Incidence of viral negative conversion (D7). Adverse events. Serious adverse events.
|Overall risk of bias||